Nephropathy Drug Fails in Diabetes Trial (CME/CE)
ATLANTA (MedPage Today) -- An investigational agent won't slow progression of chronic kidney disease in type 2 diabetes patients, and may cause cardiovascular harm, researchers reported here.
Source: MedPage Today Cardiovascular - Category: Cardiology Source Type: news
More News: Cardiology | Cardiovascular | Chronic Kidney Disease | Diabetes | Diabetes Type 2 | Endocrinology | Heart | Urology & Nephrology